KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Short-term Investments (2016 - 2025)

AbbVie (ABBV) has disclosed Short-term Investments for 14 consecutive years, with $28.0 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 9.68% to $28.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.0 million through Dec 2025, down 9.68% year-over-year, with the annual reading at $28.0 million for FY2025, 9.68% down from the prior year.
  • Short-term Investments for Q4 2025 was $28.0 million at AbbVie, down from $42.0 million in the prior quarter.
  • The five-year high for Short-term Investments was $1.5 billion in Q1 2022, with the low at $1.0 million in Q1 2025.
  • Average Short-term Investments over 5 years is $178.8 million, with a median of $28.0 million recorded in 2022.
  • The sharpest move saw Short-term Investments skyrocketed 6600.0% in 2022, then tumbled 99.51% in 2023.
  • Over 5 years, Short-term Investments stood at $84.0 million in 2021, then tumbled by 66.67% to $28.0 million in 2022, then plummeted by 92.86% to $2.0 million in 2023, then skyrocketed by 1450.0% to $31.0 million in 2024, then decreased by 9.68% to $28.0 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $28.0 million, $42.0 million, and $1.0 million for Q4 2025, Q3 2025, and Q1 2025 respectively.